Product Description
Mechanisms of Action: CAAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Communicable Diseases|Hepatitis C, Chronic|Liver Cirrhosis|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-007456-96 | P2 |
Completed |
Hepatitis C, Chronic |
2010-07-20 |
|
GS-US-227-0106 | P2 |
Terminated |
Hepatitis C, Chronic|Communicable Diseases |
2010-04-01 |
|
2008-002361-31 | P2 |
Completed |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2009-08-05 |
|
GS-US-228-0101 | P2 |
Completed |
Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Hepatitis, Alcoholic |
2009-08-01 |